Piramal Pharma Q1 FY27: posts net loss of ₹69.39 crore, revenue up 17%
Piramal Pharma (BSE: PPLPHARMA) said it has published its Q1 FY27 results (consolidated), reporting revenue of ₹2,270 crore (+17.4% year on year), a net loss of ₹69.39 crore (+15.1%), earnings per share of ₹-0.52. The company is valued at about ₹26,457 crore.
What happened
Piramal Pharma (BSE: PPLPHARMA) informed the stock exchanges on 27 October 2026 at 08:59 PM that it has published its Q1 FY27 results (consolidated), reporting revenue of ₹2,270 crore (+17.4% year on year), a net loss of ₹69.39 crore (+15.1%), earnings per share of ₹-0.52.
Company snapshot
Piramal Pharma is a small-cap company in the Healthcare sector, with a market value of about ₹26,457 crore.
The stock last traded at ₹198.7, against a 52-week range of ₹132.3–₹231.9 (14.3% below the high).
Before this filing the shares had moved −9.1% over the month and +5.4% over three months. Average daily turnover over the last 20 sessions was about ₹49.95 crore.
Promoters held 34.80% at the end of Q1 FY27, down 0.06% points from the previous quarter. Foreign institutions owned 12.52% and domestic institutions 14.57%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,934 | -81.7 | -0.62 |
| Q2 FY26 | 2,044 | -99.2 | -0.75 |
| Q3 FY26 | 2,140 | -136.2 | -1.03 |
| Q4 FY26 | 2,752 | -8.8 | -0.07 |
| Q1 FY27 | 2,270 | -69.4 | -0.52 |
What history shows
BCEIE's records show 1 previous results filing from the company since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.8% over five days; 55% of them rose the next day.
Market-wide, 9,800 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 27 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Piramal Pharma Limited (PPLPHARMA.NS) Stock Price, News, Quote & History
- Piramal Pharma bets on complex peptides, ADCs as rivals expand into GLP-1 drugs
- Piramal Pharma Limited Rights Issue 2023-16.08.23 For Shares Estimates – BSE:PLPHAR_RE
- Piramal Pharma Share Price Today Down 2.44%: What It Shows
- Piramal Pharma opens in-house sterility testing suite in $85m US expansion
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.